| Similar Articles |
|---|
 |
The Motley Fool
June 16, 2010
Ryan McBride |
Genzyme Annual Meeting Remarkably Mundane, Despite Rocky Year Genzyme's annual meeting was over in about an hour, and although the company took some hard questions from a shareholder, it appears that chairman and CEO Henri Termeer and the rest of the company's directors were easily reelected to serve on the board of directors.   |
The Motley Fool
September 23, 2010
Ryan McBride |
Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault. |
The Motley Fool
October 4, 2010
Ryan McBride |
Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share. |
The Motley Fool
September 11, 2010
Luke Timmerman |
Genzyme Cutting 1,000 Jobs Over Next 15 Months The biotech powerhouse has had a tough stretch of late, and now it says it must lay off some of its workforce. |
The Motley Fool
November 19, 2009
Brian Orelli |
This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme. |
The Motley Fool
July 26, 2010
Ryan McBride |
How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis |
The Motley Fool
November 24, 2010
Brian Orelli |
Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant. |
The Motley Fool
February 17, 2010
Brian Orelli |
Execute Well or You're Out Genzyme needs to show investors that it can rebuild. |
The Motley Fool
February 23, 2010
Brian Orelli |
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. |
The Motley Fool
June 15, 2010
Ryan McBride |
Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week. |
The Motley Fool
October 22, 2009
Brian Orelli |
The Gift That Keeps on Giving Genzyme's manufacturing issues just won't go away. Four months after the company announced that it had shut down a manufacturing plant because of viral contamination, its stock is still dealing with the aftermath. |
The Motley Fool
July 26, 2010
Brian Orelli |
Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete? |
The Motley Fool
March 3, 2011
Ryan McBride |
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players. |
The Motley Fool
August 20, 2010
Brian Orelli |
This Billionaire Likes Biotech. Should You? It depends on how much you trust management. |
The Motley Fool
January 5, 2010
Brian Orelli |
A Deal Manufactured by Necessity Genzyme gets some help from a new friend. |
The Motley Fool
August 30, 2010
Ryan McBride |
Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams. |
The Motley Fool
June 16, 2009
Brian Orelli |
Going Viral, but Not in a Good Way Genzyme's manufacturing problems with viruses underscore the complexity of manufacturing biologic drugs compared to small molecule drugs. |
The Motley Fool
March 3, 2009
Brian Orelli |
A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals. |
Chemistry World
October 5, 2010
Andrew Turley |
Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board. |
The Motley Fool
July 23, 2009
Brian Orelli |
This Too Shall Pass ... Like a Kidney Stone Demand outstrips supply? Boo-hoo. Lowered guidance because a company can't make enough to keep up with demand. Example: Genzyme |
The Motley Fool
June 10, 2010
Brian Orelli |
Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday. |
Pharmaceutical Executive
March 1, 2006
Sara Calabro |
Genzyme: The Price of Success Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism. |
The Motley Fool
January 29, 2008
Brian Lawler |
Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec. |
The Motley Fool
July 12, 2006
Brian Lawler |
Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share. |
The Motley Fool
April 24, 2008
Brian Lawler |
FDA Stings Genzyme Earnings A nasty surprise hurts the drug developer's first quarter results. |
The Motley Fool
April 8, 2010
Brian Orelli |
Is Icahn Stuck in the Station? Saving Genzyme's train wreck may be difficult. |
The Motley Fool
February 3, 2010
Brian Orelli |
Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease. |
The Motley Fool
March 23, 2010
Brian Orelli |
Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next? |
The Motley Fool
January 9, 2008
Brian Lawler |
Tracking Genzyme The biopharma updates investors on what to expect for 2008. |
The Motley Fool
January 26, 2005
John Bluis |
Genzyme Feels the Heat Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease. |
The Motley Fool
July 7, 2010
Brian Orelli |
That's Gotta Hurt: Recommending the Competition Supply constraints continue to plague Genzyme. |
The Motley Fool
February 25, 2011
Brian Orelli |
Minor Delay, Major Missed Opportunity Protalix and Pfizer's Gaucher disease drug gets delayed. |
The Motley Fool
June 8, 2010
Ryan McBride |
Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks. |
The Motley Fool
June 21, 2010
Erin Kutz |
Curis Misses Mark in Drug Trial; Genzyme Elects Board; GTC Cuts Jobs; and More Boston-Area Life Sciences News These drug and biomedical companies made news last week. |
The Motley Fool
November 18, 2008
Brian Orelli |
Genzyme Grounded for Thanksgiving The biotech won't get a decision on Myozyme until February. |
The Motley Fool
April 20, 2006
John Bluis |
Investors Jump Ship at Genzyme Clearly, Genzyme continues to invest in its business for the long term. That's the type of approach that can create a steady stream of market-beating returns for investors if they're willing to trust management. |
The Motley Fool
December 1, 2009
Brian Orelli |
Pfizer Takes In an Orphan on the Cheap Steal is a pretty accurate term for the price Pfizer paid for Protalix BioTherapeutics' taliglucerase alfa. |
The Motley Fool
February 27, 2009
Brian Orelli |
Double Approvals, Accelerated Growth Genzyme gets a pair of approvals -- one from each side of the Atlantic -- for two different products. |
The Motley Fool
September 6, 2006
Brian Lawler |
AnorMED's Tumultuous Year A takeover attempt follows management shakeups at the biopharmaceutical firm. Investors, take note. |
The Motley Fool
June 30, 2010
Ryan McBride |
Reports: Biogen Picks Exelixis Chief George Scangos as New CEO George Scangos, a microbiologist by training, has been CEO of the South San Francisco-based cancer drug developer Exelixis since 1996, and takes over at Biogen immediately. |
The Motley Fool
September 25, 2009
Brian Orelli |
Genzyme's Good News. Finally! It's been awhile, hasn't it? |
The Motley Fool
January 30, 2009
Brian Orelli |
Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%. |
The Motley Fool
January 29, 2010
Brian Orelli |
Icahn Back to Batter Biogen The old guy has tenacity. |
Chemistry World
April 24, 2008
James Mitchell Crow |
FDA takes tough line on biologic drug The US Food and Drug Administration has rejected an application from biotechnology firm Genzyme to make its already-approved, protein-based drug Myozyme in larger batches. |
The Motley Fool
June 11, 2008
Brian Lawler |
He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head. |
The Motley Fool
May 29, 2008
Brian Lawler |
Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors. |
The Motley Fool
March 2, 2004
David Nierengarten |
Genzyme's Oncology Acquisitions The biotech gobbles up two smaller firms for their cancer treatment pipelines. |
The Motley Fool
July 18, 2005
Stephen D. Simpson |
Rare Diseases Mean Solid Growth for Genzyme Genzyme doesn't target well-known diseases, but then neither does the competition. Valuing these shares is a bit tricky. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
